Literature DB >> 19512973

Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?

Ana Stefanovic1, Brigitta Brandner, Elissa Klaassen, Roman Cregg, Mayavaty Nagaratnam, Lesley M Bromley, Ravi K Das, Susan L Rossell, Celia J A Morgan, H Valerie Curran.   

Abstract

Acute administration of the N-methyl-D-aspartate receptor antagonist ketamine induces schizophrenia-like symptoms in healthy volunteers; furthermore, a window on ketamine's chronic effects is provided by regular recreational users. The current study utilized both acute ketamine administration in healthy volunteers and chronic ketamine abusers to investigate semantic processing, one of the key cognitive deficits in schizophrenia. Semantic processing was examined using a semantic priming paradigm. In experiment 1, acute effects of low (75 ng/mL) and high (150 ng/mL) ketamine doses were compared in a placebo-controlled double-blind independent group design with 48 participants. In experiment 2, 19 regular recreational ketamine users were compared with 19 ketamine-naive polydrug controls and 26 non-drug-using controls. In both experiments, semantic priming parameters were manipulated to distinguish between ketamine's effects on (1) automatic and strategic processing and (2) the facilitation and inhibition components of semantic priming for strongly (directly) related primes and targets. Acute effects of ketamine on semantic priming for weakly (indirectly) related primes and targets were also assessed in experiment 1. Acutely, ketamine impaired the employment of strategic mechanisms but not automatic processing within both the direct and indirect semantic priming tasks. Acute ketamine administration also induced clear schizophrenia-like symptoms. Schizotypy traits in the cognitive and perceptual domains tended to correlate with increased semantic priming in long-term ketamine users. In summary, acute and chronic ketamine-induced changes partially mirrored the findings on semantic priming in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19512973     DOI: 10.1097/JCP.0b013e31819a4b91

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  10 in total

Review 1.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 2.  The assessment of schizotypy and its clinical relevance.

Authors:  Oliver J Mason
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

3.  Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys.

Authors:  Pierre Pouget; Nicolas Wattiez; Sophie Rivaud-Péchoux; Bertrand Gaymard
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

4.  Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.

Authors:  Masakuni Horiguchi; Mei Huang; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2011-03-25       Impact factor: 4.530

5.  Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggest Dentate Gyrus Pathology Linked to NMDA Receptor Hypofunction.

Authors:  Nina Vanessa Kraguljac; Matthew Carle; Michael A Frölich; Steve Tran; Michael A Yassa; David Matthew White; Abhishek Reddy; Adrienne Carol Lahti
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2021-10-12

6.  Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans.

Authors:  Tom P Freeman; Celia J A Morgan; Elissa Klaassen; Ravi K Das; Ana Stefanovic; Brigitta Brandner; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2009-05-13       Impact factor: 4.530

7.  Performance on a probabilistic inference task in healthy subjects receiving ketamine compared with patients with schizophrenia.

Authors:  Simon Evans; Basil Almahdi; Pervez Sultan; Imrat Sohanpal; Brigitta Brandner; Tracey Collier; Sukhi S Shergill; Roman Cregg; Bruno B Averbeck
Journal:  J Psychopharmacol       Date:  2012-03-02       Impact factor: 4.153

Review 8.  Ketamine plus Alcohol: What We Know and What We Can Expect about This.

Authors:  Natalia Harumi Correa Kobayashi; Sarah Viana Farias; Diandra Araújo Luz; Kissila Márvia Machado-Ferraro; Brenda Costa da Conceição; Cinthia Cristina Menezes da Silveira; Luanna Melo Pereira Fernandes; Sabrina de Carvalho Cartágenes; Vânia Maria Moraes Ferreira; Enéas Andrade Fontes-Júnior; Cristiane do Socorro Ferraz Maia
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

9.  RETRACTED: Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggests Dentate Gyrus Pathology Linked to N-Methyl-D-Aspartate Receptor Hypofunction.

Authors:  Nina Vanessa Kraguljac; Matthew Carle; Michael A Frölich; Steve Tran; Michael A Yassa; David Matthew White; Abhishek Reddy; Adrienne Carol Lahti
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-02-28

Review 10.  On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods.

Authors:  C E Strong; Mohamed Kabbaj
Journal:  Neurobiol Stress       Date:  2018-09-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.